Key clinical point: A MET inhibitor may be able to overcome MET-driven resistance to epidermal growth factor receptor (EGFR)–targeted therapy in non–small cell lung cancer.
Major finding: Objective response rates to osimertinib/savolitinib in two cohorts were 52% and 25%, respectively.
Study details: Data from two cohorts of a phase 1b trial including 94 patients with EGFR-mutant non–small cell lung cancer.
Disclosures: The TATTON trial is sponsored by AstraZeneca. Dr. Sequist reported serving as an advisory board member and receiving research support and honoraria from the company. Dr. Herbst reported receiving research support from AstraZeneca, Eli Lilly, and Merck, and has served as a consultant for AstraZeneca, Eli Lilly, Genentech/Roche, Merck, NextCure, and Pfizer.